AUTHORS
Andre C. Schuh Sr, BSc, MD, FRCPC, Christopher Lemieux, MD2, Mohamed Elemary, MD,MSc,PhD,FRCP3, Curtis Marcoux4, Yomna Eissa5, Jerry Yang6, Ali Farjah7
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, ON, Canada
2 CHU de Québec – Université Laval, Laval, QC, Canada
3 Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK, Canada
4 Dalhousie University, Halifax, NS, Canada
5 London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
6 Astellas Pharma Canada, Inc., Markham, ON, Canada
7 Astellas Pharma Canada, Inc., Markham, ON, Canada
ABSTRACT
Background: Gilteritinib was approved in Canada in December 2019 for the treatment of adults with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutations, including both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations. While the efficacy and safety have been demonstrated in clinical studies, limited real-world evidence is available from Canadian clinical practice describing treatment patterns and utilization of gilteritinib. This study aimed to characterize real-world utilization of gilteritinib in adults with R/R FLT3-mutated (FLT3mut+) AML enrolled in a Canadian patient support program (PSP). Data collected included patient demographics, geographic and practice-setting distribution, treatment duration, discontinuation patterns, and dose modification practices.
Methods: This retrospective descriptive study used patient-level data from adults receiving on-label gilteritinib for R/R FLT3mut+ AML through the Canadian PSP between February 4, 2020 and April 9, 2026. Data collected included age, province, practice setting initial prescription (academic or community), FLT3 mutation subtype, treatment duration, reasons for discontinuation, and dose modifications. Data were summarized using descriptive statistics. FLT3 mutation analyses were limited to patients with available mutation data from February 2024 onward, and dose modification analyses were restricted to patients with documented dose changes.
Results: A total of 306 patients receiving on-label gilteritinib through the Canadian PSP were included. Most patients initiated treatment in academic centers (n=268, 87.6%) and were from Ontario (n=160, 52.3%) or Quebec (n=67, 21.9%). Median (interquartile range, IQR) age was 66 (21) years. Among patients with available FLT3 mutation data (n=38), 31 (81.6%) had FLT3-ITD mutations, 6 (15.8%) had FLT3-TKD mutations, and 1 (2.6%) had both mutations. Treatment discontinuation data were available for 264 patients. Median (IQR) treatment duration was 141 (275) days (mean [standard deviation, SD], 262 [323] days), with the longest duration on therapy observed at 1875 days. Overall, in patients with available data, 57 of 264 (21.6%) patients remained on treatment for ≥1 year, of whom 4 of 57 (7.2%) remained on treatment for ≥2 years. The most common reasons for discontinuation were death (n=110/264, 41.7%), physician decision (n=79/264, 29.9%), disease progression (n=28/264, 10.6%), and transition to public reimbursement (n=23/264, 8.7%). Dose modification data were available for 55 patients. The most common starting dose was 120 mg (n=49, 89.1%). Of the 49 patients initiating gilteritinib at 120 mg, 29 (59.2%) subsequently reduced their dose to 80 mg and 11 (22.4%) escalated their dose to 200 mg. Reasons for dose modifications were not captured. At data cutoff, 41 patients remained enrolled in the PSP.
Conclusion: In this real-world analysis of patient data from the Canadian PSP, gilteritinib real-world utilization was consistent with findings from the phase 3 ADMIRAL study of gilteritinib in patients with R/R FLT3mut+ AML (Perl AE, et al. N Engl J Med. 2019;381(18):1728-1740.). Gilteritinib was utilized across diverse practice settings in Canada, demonstrating flexible dosing strategies and durable treatment exposure in a subset of patients with R/R FLT3mut+ AML. Although the rationale for dose adjustments was not captured, the observed dose modification patterns demonstrated heterogeneity in real-world practice, which may reflect individualized treatment approaches based on tolerability, post-transplant management strategies, or response assessment. Further studies capturing clinical outcomes and physician decision-making will help better contextualize these findings.
DISCLOSURES
Andre C. Schuh Sr, BSc, MD, FRCPC: Kite/Gilead - Research Funding; Johnson & Johnson - Research Funding; Pfizer - Research Funding; Glycomimetics - Research Funding; Servier - Research Funding; Loxo - Research Funding; BMS - Research Funding; Astellas - Research Funding; Merck - Research Funding; Amgen - Research Funding; Takeda - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Novartis - Research Funding; Daiichi-Sankyo - Research Funding; Syndax - Research Funding; Astellas - Consultancy (Includes expert testimony); Paladin - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Teva - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony)